SCM LifeScience Co

SCM LifeScience Co Capital Intensity

The Capital Intensity Ratio of SCM LifeScience Co (298060.KQ) as of Nov 19, 2026 is 218.10 %. In the previous year, Capital Intensity Ratio was 2,809.13 % — a change of -92.24% (lower).

Capital Intensity

218.10 %

YoY

-92.24%

Last updated:

Capital Intensity Ratio of SCM LifeScience Co is 2025 218.10 % . Capital Intensity Ratio of SCM LifeScience Co was 2024 2,809.13 % . It decreases by -92.24% lower compared to the previous year.

The SCM LifeScience Co Capital Intensity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Intensity
Date
Capital Intensity
Jan 1, 2018
152,484.56 KRW
Jan 1, 2019
24,354.34 KRW
Jan 1, 2020
23,840.80 KRW
Jan 1, 2021
12,303.52 KRW
Jan 1, 2022
8,338.75 KRW
Jan 1, 2023
3,651.55 KRW
Jan 1, 2024
2,809.13 KRW
Jan 1, 2025
218.10 KRW
The SCM LifeScience Co Capital Intensity history
YEARCapital IntensityYoY
218.10 %-92.24%
2,809.13 %-23.07%
3,651.55 %-56.21%
8,338.75 %-32.22%
12,303.52 %-48.39%
23,840.80 %-2.11%
24,354.34 %-84.03%
152,484.56 %+601.88%
21,725.03 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SCM LifeScience Co Stock analysis

What does SCM LifeScience Co do? SCM LifeScience Co Ltd is a biotechnology company headquartered in Incheon, South Korea. The company focuses on the development and production of cell therapy products, including adult stem cell therapies. It also engages in agency testing for cell production and quality assurance, as well as providing adult stem cell consulting services. Additionally, SCM LifeScience operates in the cosmetics and hair growth protein manufacturing sectors. The company has 55 full-time employees. SCM LifeScience completed its initial public offering (IPO) on June 17, 2020. Its stock is listed under the ticker 298060.KQ on the Korean stock exchange, with an ISIN code of KR7298060005. The company's website is http://www.scmlifescience.com/. SCM LifeScience operates within the healthcare sector, specifically within the biotechnology industry. It does not provide details on its founding year, specific product names, or financial figures beyond the IPO date and employee count. The company's activities span drug development for stem cell therapy, cell production testing, and manufacturing of related products. SCM LifeScience Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SCM LifeScience Co stock

Capital Intensity Ratio of SCM LifeScience Co is 218.10 % in 2025.

Capital Intensity Ratio of SCM LifeScience Co changed from 2,809.13 % to 218.10 %, representing a -92.24% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Intensity Ratio SCM LifeScience Co since 2006 – with annual values, charts, and detailed analysis.

Capital intensity measures the amount of assets needed to generate each unit of revenue. Lower ratios indicate asset-light business models.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Capital Intensity Ratio's SCM LifeScience Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Capital Intensity Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Capital Intensity Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — SCM LifeScience Co

All Key Metrics — SCM LifeScience Co